ANI Pharmaceuticals, Inc.
General ticker "ANIP" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.7B (TTM average)
ANI Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -12.9%.
Estimated limits based on current volatility of 1.6%: low 71.23$, high 73.56$
Factors to consider:
- Total employees count: 970 (+8.1%) as of 2025
- US accounted for 96.5% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Commercialization failure, Market competition, Contract manufacturer reliance, Regulatory and compliance, Manufacturing disruptions
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [64.58$, 101.29$]
- 2026-12-31 to 2027-12-31 estimated range: [65.05$, 103.01$]
Financial Metrics affecting the ANIP estimates:
- Positive: with PPE of 10.3 at the end of fiscal year the price was neutral
- Positive: 11.37 < Operating cash flow per share per price, % of 11.43
- Positive: 11.29 < Operating profit margin, % of 12.58
- Positive: -51.61 < Industry operating profit margin (median), % of -17.91
- Positive: 5.14 < Return on assets ratio (scaled to [-100,100]) of 5.16
- Positive: Inventory ratio change, % of -4.14 <= -3.92
- Positive: 34.41 < Shareholder equity ratio, % of 37.54 <= 42.26
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 1.24 <= 1.42
Short-term ANIP quotes
Long-term ANIP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $486.82MM | $619.72MM | $882.98MM |
| Operating Expenses | $439.85MM | $619.14MM | $771.89MM |
| Operating Income | $46.97MM | $0.58MM | $111.09MM |
| Non-Operating Income | $-27.10MM | $-22.80MM | $-15.30MM |
| Interest Expense | $26.94MM | $17.60MM | $20.06MM |
| R&D Expense | $34.29MM | $44.58MM | $51.66MM |
| Income(Loss) | $19.87MM | $-22.21MM | $95.79MM |
| Taxes | $1.09MM | $-3.69MM | $17.45MM |
| Net Income(Loss)* | $18.78MM | $-18.52MM | $78.34MM |
| Stockholders Equity | $432.75MM | $403.68MM | $540.72MM |
| Inventory | $111.20MM | $136.78MM | $143.07MM |
| Assets | $904.42MM | $1,284.47MM | $1,440.38MM |
| Operating Cash Flow | $118.96MM | $64.02MM | $185.22MM |
| Capital expenditure | $18.51MM | $16.95MM | $34.32MM |
| Investing Cash Flow | $-18.51MM | $-404.72MM | $-34.32MM |
| Financing Cash Flow | $67.44MM | $264.94MM | $-9.94MM |
| Earnings Per Share** | $1.04 | $-0.96 | $3.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.